leucine rich repeats and death domain containing 1Genealiases: []
Q-omics provides the consensus-scored LRRD1 profile across patient tissues and cancer cell-line models. LRRD1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, LRRD1 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, LRRD1 RNA expression shows 15,834 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, HNSC, and UVM as cancer lineages where LRRD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRD1 survival associations across molecular data types. LRRD1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRD1 RNA expression–survival associations across cancer types. High LRRD1 expression shows unfavorable associations in KIRC, DLBC, UVM, LUSC and READ, but favorable associations in UCS. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for LRRD1 RNA expression.
This table summarizes LRRD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LRRD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRD1 shows higher tumor expression in HNSC, KIRC, CHOL, KICH, KIRP and STAD. The HNSC box plot shows higher LRRD1 RNA expression in tumor versus normal tissue (log2 FC = +0.034, t-test p < 0.001).
This table shows molecular features associated with LRRD1 in patient tissues and cancer cell lines. In patient samples, LRRD1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
